Biotech Values

[drbio45]

from an investment perspective data on depo's formulation of gabapentin are due out soon. It strikes me as a low risk event given the proven efficacy for neurontin in post-herpetic neuralgia. I'm just trying to figure out if the street will care much based on the commercial potential of the product

Xenoport has a prodrug of gabapentin lisensed to glaxo
xenoport has a billion dollar market cap. their drug has more side effects than depo's. xnpt is in trials for restless leg.

depomed licensed a patent for hot flashes. Depomed's gabapentin gr will be on the market before xnpt.

valuation wise which one is cheaper